Abstract: The present invention relates to titanium and zirconium compounds of the formulae (R1—O?yX?O—R2—W)z??I wherein each R1 is independently selected from the group consisting of alkyl radicals having from 1 to 8 carbon atoms; R2 is a divalent radical selected from the group consisting of alkylenes having 1 to 15 carbon atoms, arylene and alkyl substituted arylene groups having 6 to 10 carbon atoms; W is an epoxy group; and y is an integer of from 1 to 3, z is an integer of from 1 to 3 and the sum of y and z equals 4; and X is titanium or zirconium.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: A process for preparing N-acyl, N-sulfonyl and N-phosphoryl substituted isoserine esters in which a metal alkoxide is reached with a &bgr;-lactam.

Abstract: This invention relates to an organothiosulfonato Au(I) complex having the formula [A—SO2S—Au—SSO2—A]n−M+n wherein M is a cationic counter ion; A is a substituted or unsubstituted organic group; and n is 1 to 4; and wherein the compound is symmetrical. It further relates to the synthesis of said compounds.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of such complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.

Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.

Abstract: The invention provides methods for treating cancer and vanadium compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: The invention relates an ionic metal complex represented by the general formula (1): wherein M is an element of groups 3-15 of the periodic table; Aa+ represents a metal ion, onium ion or proton; X1 represents O, S or NR5R6; each of R1 and R2 independently represents H, a halogen, a C1-C10 alkyl group or C1-C10 halogenated alkyl group; R3 represents a C1-C10 alkylene group, C1-C10 halogenated alkylene group, C4-C20 aryl group or C4-C20 halogenated aryl group; R4 represents a halogen, C1-C10 alkyl group, C1-C10 halogenated alkyl group, C4-C20 aryl group, C4-C20 halogenated aryl group or X2R7; X2 represents O, S or NR5R6; each of R5 and R6 represents H or a C1-C10 alkyl group; and R7 represents a C1-C10 alkyl group, C1-C10 halogenated alkyl group, C4-C20 aryl group or C4-C20 halogenated aryl group. The ionic metal complex can be used as a supporting electrolyte for electrochemical devices, a polymerization catalyst of polyolefins and so forth, or a catalyst for organic synthesis.

Abstract: The invention provides a process for producing an &agr;-hydroxy-carbonyl compound or an &agr;-protected hydroxy-carbonyl compound by reacting a carbonyl compound (I) with a compound (II) and a compound (III). The compounds (I), (II) and (III) are defined below. R1, R2, R3 and R4 are an organic group. PG is a protective group for hydroxy group. Y is R4N, S or O. The product is useful in pharmacology.

Abstract: This invention relates to an organomercapto Au(I) complex having the formula [(M—SOL)n—A—S—Au—S—A—(SOL—M)n]M wherein M is a cationic counterion; SOL is a solubilizing group: A is a substituted or unsubstituted divalent organic linking group; and n is 1 to 4 and wherein the compound is symmetrical. It further relates to a method of manufacturing an organomercapto Au(I) complex comprising reacting an Au (I) complex with an organomercapto ligand and isolating the resulting organomercapto Au(I) complex from the reaction mixture.

Abstract: The present invention is directed to complexes comprising iron in the ferric state and a hydroxypyrone. The present invention is also directed to methods of making such complexes and to the use of the complexes in the treatment and prevention of iron deficiency disorders including iron deficiency anaemia.

Abstract: Methods of treating fungal infections comprise administering a therapeutically effective amount of a compound described by Formulas [(I)-(VI)]. Examples of fungal infections include Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Fusarium solani, and combinations thereof.

Abstract: The reduction of a titanium tetrahalide with titanium in the presence of an ether which forms an adduct with titanium trihalide, wherein an adduct insoluble in said ether is produced.

Abstract: A treatment for cancer and compounds for use therewith are provided. The compounds treat cancer by correcting a TATA box lesion in DNA that leads to the cancer's uncontrolled cell proliferation. The preferred compounds each contain strontium; iodine; ascorbic acid; and a diamagnetic ion, either bismuth, zinc, or potassium. These components orient the compound, transport it to the lesion, dissociate the aberrational bonds of the lesion, hydrogenate the dissociated TATA nucleotides at the lesion, and reconvert the lesion's chemical structure to that of normal DNA.

Abstract: Novel compounds having one group 13 element bound with one mono- or di-anionic tridentate ligand, a method of preparation thereof and use thereof as a copolymerization catalyst.

Abstract: Organic complexes of vanadium are provided, having the general structure VL3, where V is vanadium(III) and L is a monoprotic bidentate ligand that forms a five-membered, unsaturated vanadium containing ring, having vanadium coordinating oxygen or sulfur ring heteroatoms, and where the vanadium containing ring is fused to a six-membered heterocyclic ring. Preferably L is a hydroxypyrone or a hydroxypyridinone. The complexes have a number of uses, including the treatment of elevated blood glucose and related disorders, treatment of proliferative disorders, etc.

Abstract: An acetal, wherein the acetal is 2,2-di(tetrahydrofurfuryloxy)propane as well as processed for producing the acetal and methods of using the acetal.

Abstract: Organovanadium complexes, and more specifically hydroxyoxovanadium(V), &mgr;-oxo dimeric oxovanadium(V) and cis-dioxovanadium(V) complexes, are provided. The complexes may be formulated into a pharmaceutical composition. The complexes and/or compositions may be used in the treatment of a variety of disease states, including use as anti-proliferative and/or anti-metastatic agents and/or to treat drug resistant tumors and/or to methods of reducing the ability of tumors to metastasize and/or for the treatment of diabetes, arthritis, multiple sclerosis, diseases involving passageways of the body, and autoimmune diseases including but not limited to psoriasis and lupus.

Abstract: The disclosure describes a process for preparing a TiCl.sub.3 ether complex, such as TiCl.sub.3 (THF).sub.3, by reaction of corresponding TiCl.sub.4 ether complex with a metal powder, which produces a soluble metal chloride complex, in ether solvent. The TiCl.sub.3 ether complex that is prepared has a low aluminum content.

Abstract: Novel chiral boron and aluminum hydride complexes, compositions comprising the chiral hydride complexes, and methods for their synthesis and use are described. The novel chiral hydride complexes are of the formulas:MBH.sub.4-n-a (R*).sub.n (R').sub.a ;MBH.sub.2-b (R**) (R').sub.b ;MBH(R***);MBH(R*) (R");MAlH.sub.4-n-a (R*).sub.n (R').sub.a ;MAlH.sub.2-b (R**)(R').sub.b ;MAlH(R***); andMAlH(R*) (R"),whereinM is Na.sup.+, Li.sup.+ or K.sup.+ ;each R* is independently a monodentate chiral ligand;R** is a bidentate chiral ligand;R*** is a tridentate chiral ligand;R' is a monodentate achiral ligand;R" is a bidentate achiral ligand;n is 1-3;a is 0-2; andb is 0-1,with the proviso that n+a.ltoreq.3, and with the further proviso that when R** is S-BINOL, M is not Li.sup.+.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: The subjects of this invention are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. The compositions have been developed to provide pharmaceutically acceptable gallium bioavailability together with low toxicity, particularly for oral administration. Compositions included in this invention should be useful in providing gallium to humans and other animals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of certain bone diseases, certain cancers, and certain disorders of calcium homeostasis.

Abstract: Disclosed is a process for producing novel optically active titanium alkoxide complexes which are excellent in catalytic activity and enantio-selectivity in carbon-carbon bond forming reactions (for example, Ene reaction, hetero-Diels-Alder reaction, Aldol reaction) and have high stability. The present process comprises reacting (R),(S),(RS)-catalysts or mixtures thereof selected from among optically active or racemic titanium alkoxide complexes represented by the following general formula (1), etc.: ##STR1## wherein R.sup.1 represents a methyl, lower alkoxy or trihalogeno group; R.sup.2 represents a hydrogen or halogen atom; R.sup.3 represents a hydrogen atom or a methyl group; and R.sup.4 represents a lower alkyl group, or R.sup.1 and R.sup.2 may form together a cyclo ring;with chiral activators [(R),(S),(RS)-diols or mixtures thereof, but excluding reactions between a racemic modification and another racemic modification] to thereby activate exclusively one of the enantiomers.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: The subjects of this invention are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. The compositions have been developed to provide pharmaceutically acceptable gallium bioavailability together with low toxicity, particularly for oral administration. Compositions included in this invention should be useful in providing gallium to humans and other animals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of certain bone diseases, certain cancers, and certain disorders of calcium homeostasis.

Abstract: A process for preparing metallocene complexes of the general ##STR1## in which the substituents have the following meanings:M is titanium, zirconium, hafnium, vanadium, niobium or tantalum,X is fluorine, chlorine, bromine, iodine, hydrogen, C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl or --OR.sup.5,where R.sup.5 is C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl, alkylaryl, aryl-alkyl, fluoroalkyl or fluoroaryl with, in each case, 1 to 10 carbon atoms in the alkyl radical and 6 to 20 carbon atoms in the aryl radical,R.sup.1 to R.sup.4 and R.sup.6 to R.sup.9 are hydrogen, C.sub.1 -C.sub.10 -alkyl, 5- to 7-membered cycloalkyl which can in turn carry C.sub.1 -C.sub.10 -alkyls as substituents, or C.sub.6 -C.sub.15 -aryl or aryl-alkyl, it also being possible where appropriate for two adjacent radicals together to be cyclic groups having 4 to 15 carbon atoms, or Si(R.sup.10).sub.3 withR.sup.10 being C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl or C.sub.3 -C.sub.

Abstract: Aluminum amidinate compounds of the formula ##STR1## wherein R.sup., R.sup.2, and R.sup.3 are selected from the group consisting of C.sub.1 to C.sub.50 alkyl, aryl, and silyl groups, X is an anionic ligand, preferably a hydrocarbyl, n=0 or 1, L, if present, is a labile Lewis base ligand, preferably having an oxygen, nitrogen, or phosphorus atom donating a lone pair of electrons to the aluminum center, and A.sup.- is an anion which balances the charge of the aluminum cation and only weakly if at all coordinates to the aluminum center and preferably contains boron, are disclosed. These compounds are useful as olefin polymerization catalysts without the need for cocatalysts or transition metal species.

Abstract: The present invention relates to a method of producing a platinum (II) complex represented by the formula (A) below characterized by reacting a dichloroplatinum (II) complex represented by the formula (B) below and a tetronic acid derivative represented by the formula (C) below in the presence of a silver salt and a barium salt.

Abstract: The invention provides hydroxamic acid derivatives of the general formula ##STR1## wherein Bz represents benzyl; R.sup.1 represents cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; R.sup.2 represents a saturated 5- to 8-membered monocyclic or bridged N-heterocyclic ring, which N-heterocyclic ring is attached via the N atom and when it is monocyclic, optionally contains NR.sup.4, O, S, SO or SO.sub.2 as a ring member and/or is optionally substituted on one or more C atoms by hydroxy, lower alkyl, lower alkoxy, oxo, ketalized oxo, amino, mono(lower alkyl)amino, di(lower alkyl)amino,carboxy, lower alkoxycarbonyl, hydroxy-methyl, lower alkoxymethyl, carbamoyl, mono(lower alkyl)-carbamoyl, di(lower alkyl)carbamoyl or hydroxy-imino; R.sup.3 represents a 5- or 6-membered N-heterocyclic ring which (a) is attached via the N atom, (b) optionally contains N, O and/or S, SO or SO.sub.

Abstract: Novel complexes of paramagnetic ions and compounds bearing long acyl chains have been synthesized as magnetic resonance imaging contrast agents. These novel liposoluble contrast agents may be administered alone, or with lipids, suspending agents or other additives. The lipids may be in the form of liposomes, micelles or lipid emulsions. The contrast agents of the invention have particular use in magnetic resonance imaging of the liver, blood pool and reticuloendothelial system.

Abstract: Novel platinum(II) complexes represented by the general formula ##STR1## in which R.sub.1 represents a lower hydrocarbon radical of 1 to 3 carbon atoms, R.sub.2 and R.sub.3 each independently represent a hydrogen atom or a lower hydrocarbon radical of 1 to 3 carbon atoms, or R.sub.2 and R.sub.3 together may form --(CH.sub.2).sub.4 --or --(CH.sub.2).sub.5 --, Y and Z each independently represent an ammonia molecule or a monodentate amine of 1 to 7 carbon atoms or X and Y together may form a bidentate diamine of 2 to 10 carbon atoms, and X.sup.- represents an inorganic acid anion or an organic carboxylate anion, and agents for treating malignant tumors which contain them as effective components. The compounds are effective against cisplatin-resistant tumors, are soluble enough for intravenous administration, are stable in aqueous solution, and have excellent antitumor activity.

Abstract: 2,4-Heteroatom-substituted-molybdena-3,3-dioxocyclopentane hydro-conversion catalysts are disclosed. In some embodiments, inexpensive bulk catalysts in accordance with the present invention are synthesized from bulk triglyceridic epoxides or fatty acids.

Abstract: Novel trisstannoxanes are prepared by the reaction of a dialkyltin oxide with a trihydroxy compound such as 1,1,1-tris(hydroxymethyl)propane. They may be employed as catalysts for the preparation of branched polyesters from macrocyclic polyester oligomers. They are less susceptible than previously known catalysts to the presence of acidic impurities in the oligomer compositions.

Abstract: A platinum(II) complex represented by the general formula (A), ##STR1## in which R.sub.1 represents a hydrocarbon radical having 1 to 10 carbon atoms, R.sub.2 and R.sub.3 each represent a hydrogen atom or a hydrocarbon radical of 1 to 10 carbon atoms, or R.sub.2 and R.sub.3, together, may form --(CH.sub.2).sub.4 -- or --(CH.sub.2).sub.5 --, and X and Y each represent an ammonia molecule or a monodentate amine having 1 to 7 carbon atoms or X and Y, together, may form a bidentate diamine having 2 to 10 carbon atoms. The compounds are useful for treating a tumor.

Abstract: A novel platinum (II) complex represented by the following formula (A): ##STR1## wherein R.sub.1 represents C.sub.1 -C.sub.5 lower hydrocarbon group, R.sub.2 and R.sub.3 represents hydrogen atom or C.sub.1 -C.sub.3 lower hydrocarbon group, the configuration of 1,2-diaminocyclohexane being cis, trans-l- or trans-d-. Since the platinum (II) complex has a strong anti-tumor activity and its toxicity is low, it is useful as an agent for treating malignant tumor.

Abstract: Ti(III) coordination complexes with ethers are prepared by the steps of (a) forming an ether complex of a Ti(IV) salt by adding a stoichiometric excess of an ether to said salt, and then (b) reducing said complex with an organometallic reducing agent such as an aluminum alkyl or a lithium compound to form a Ti(III)-ether coordination complex.

Abstract: Disclosed are pharmaceutical compositions that comprise gallium complexes of 3-hydroxy-4-pyrones. These compositions provide enhanced gallium bioavailability particularly when orally administered as compared to the gallium bioavailability achieved by use of pharmaceutical compositions containing gallium salts. Compositions included in this invention are useful in providing gallium to humans and other mammals for a wide variety of medical and veterinary applications, including the treatment, prevention, or diagnosis of hypercalcemia, certain cancers, certain disorders of calcium homeostasis, and certain bone diseases including osteoporosis, osteopenia, and Paget's disease.

Abstract: Silicon and aluminum complexes having the following formula I, II or III: ##STR1## wherein x is 0 or 1, T is H or ##STR2## each R is independently selected from the group consisting of H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.2-6 alkene, C.sub.6-12 aryl, C.sub.1-6 hydroxyalkyl, C.sub.1-6 thioalkyl, C.sub.2-12 alkoxyalkyl, C.sub.3-20 heteroaromatic, and combinations thereof, wherein R may further contain one or more atoms of a non-carbon element such as Si, Ge, Sn, P, and the like; Y is a cation, and Z is a multivalent cation, are prepared by reacting silica or alumina with a diol, in the presence of a base, while removing water formed during the reaction. Methods for producing such complexes starting with silica or alumina, and methods for converting such complexes into other silicon or aluminum-containing compounds, are disclosed.

Abstract: A process of separating one or more seleced species of ions from a solution containing the ions comprises contacting the solution with a novel composition of matter comprising a hydrocarbon chain covalently bonded to a macrocyclic compound, wherein the macrocyclic compound has at least four --A--C--C-- linkages in which A for each such linkage, is independently selected from the group consisting of O, O--CH.sub.2, S, SH.sub.2, NR, and NRCH.sub.2, with R being independently selected from the group consisting of hydrogen, alkyl and benzyl, and wherein the hydrocarbon chain has an end group ##STR1## with X being independently selected from the group consisting of lower alkyl, benzyl, phenyl, halogen, O--CH.sub.3, O--C.sub.2 H.sub.5 and O-matrix, and with matrix being independently selected from the group consisting of silica, silica gel, glass, glass fibers, titania, zirconia, alumina and nickle oxide.

Abstract: Iron complexes comprising a ferric cation in combination with at least two different ligands, at least one of which is provided by a compound being:(1) 3-hydroxy-4-pyrone or a 3-hydroxy-4-pyrone in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic hydrocarbon group of 1 to 6 carbon atoms; or(2) a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, alkoxy, alphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group of 1 to 6 carbon atoms, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; the ch

Abstract: Compounds of the formula I ##STR1## in which Me is Ti, Zr or Hf, R.sub.1 is a group transferable to aldehyde, keto or imine groups, for example methyl, allyl, vinyl or the radical of an enol or enamine, R.sub.2 is, for example, cyclopentadienyl, R.sub.3 and R.sub.4 are, for example, H or alkyl, R.sub.5 is, for example, phenyl and the C(1) and C(2) atoms are chiral and have predominantly one configuration, are suitable for use as chiral reactants for aldehydes, ketones and imines for the preparation of both enantiomers of secondary or tertiary alcohols or tertiary amines.

Abstract: An accelerator of the activity of hydrolase consisting of a coordination compound or a metal complex containing, as a ligand, an organic cyclic compound with carbonyl groups adjacent to each other in the structure shown in the following general formula I that are substantially in the same plane as each other; ##STR1## (wherein A is the cyclic compound moiety.

Abstract: This invention relates to novel compounds which are precursors for di- and triarylmethane dye precursor compounds possessing a thiolactone, dithiolactone or thioether ring-closing moiety.

Abstract: A platinum complex represented by the formula: ##STR1## where X is ##STR2## wherein R.sup.1 is a (C1-18) alkyl group, a (C1-18)alkenyl group or a group --Z--R.sup.4 in which Z is --CH.dbd.CH-- or a (C1-5)alkylene group, and R.sup.4 is a phenyl group, a hydroxyphenyl group, a (C7-12)alkoxyphenyl group, a halogenophenyl group, a nitrophenyl group, or (C8-13)alkoxycarbonylphenyl group, a cyclohexyl group having a (C1-5)alkyl substituent, ##STR3## R.sup.2 is hydrogen or a (C1-18)alkyl group, R.sup.3 is hydrogen or a (C1-3) alkyl group, R.sup.2 and R.sup.3 are linked together to form a (C2-7)alkylene group; the dotted line indicates that the bond may be either a single bond or a double bond; the chain line indicates a conjugated system; the 1,2-diaminocyclohexane moiety has a cis-, trans-l- or trans-d-configuration; and Y is an anion. This platinum complex is useful in the treatment of tumors.

Abstract: A platinum complex represented by the formula: ##STR1## wherein R.sup.1 is a (Cl-18) alkyl group, a (Cl-18)-alkenyl group or a group ----X--R.sup.5 in which X is --CH.dbd.CH-- or a (Cl-5)alkylene group, and R.sup.5 is a phenyl group, a hydroxyphenyl group, a (C7-12) alkoxyphenyl group, a halogenophenyl group, a nitrophenyl group, or (C8-13)alkoxycarbonylphenyl group, a cyclohexyl group having a (Cl--5)alkyl substituent, ##STR2## R.sup.2 is a (Cl-18 alkyl group, R.sup.3 is a hydrogen atom, or R.sup.2 and R.sup.3 are linked together to form a (C2-7)alkylene group, R.sup.4 is OH or NO.sub.3 ; the dotted line indicates that the bond may be either a single bond or a double bond; the chain line indicates a conjugated system; n is a number of from 1 to 2, and the 1,2-diaminocyclohexane moiety has a cis-, trans-l- or trans-d-configuration. This platinum complex is useful in the treatment of tumors.

Abstract: Preparation of ethylene copolymers from ethylene and polar and/or non-polar comonomers in the presence of selected nickel-containing catalysts.

Abstract: Antimony trioxide is reached with an organic mercaptan R.sup.1 --SH or R.sup.2 --OCO--(CH.sub.2).sub.n --SH (where R.sup.1 is an alkyl, alkenyl, aryl, aralkyl, cycloalkyl or heterocyclic group having from 1 to 18 carbon atoms, which optionally has sulfide bond or ether bond or a hydroxyl or carboxyl group as a substituent, R.sup.2 is a hydrogen atom or an alkyl, alkenyl, aryol, aralkyl, cycloalkyl or heterochclic group having from 1 to 18 carbon atoms, which optionally has sulfide bond or ether bond or a hydroxyl or carboxyl group as a substituent, and n is 1 to 3) in the presence of a lower aliphatic carboxylic acid to give an antimony mercaptide Sb(--SR.sup.1).sub.3 or Sb(--S--(CH.sub.2).sub.n --COOR.sup.2).sub.3 of high purity with high yield. The products are excellent in the time-dependent stability and the effect as a passivator for catalysts for catalytic cracking of hydrocarbons.

Abstract: The invention relates to new molecular complexes of general formula: ##STR1## in which R represents a straight- or branched-chain alkyl radical having from 1 to 4 carbon atoms and R.sub.1 represents one of the radicals: ##STR2## These molecular complexes are especially useful for the preparation of 2-alkyl-3-(4-hydroxybenzoyl)benzofurans.